The Federal Trade Commission’s sudden crackdown on the transgender medical industry for alleged fraud and deception has left hospitals scrambling, parents fuming, and the country asking: how did a radical agenda aimed at children go unchecked for so long?
At a Glance
- The FTC is investigating whether minors and families were deceived about the risks and outcomes of gender-affirming care
- Major hospitals have begun pausing or shutting down transgender services for minors amid fear of federal lawsuits and funding loss
- The Trump administration ended federal support for these medical interventions, sparking regulatory scrutiny and a firestorm of public debate
- Detransitioners and whistleblowers allege decades of misinformation, lack of informed consent, and harm to vulnerable youth
FTC Launches Investigation into Gender-Affirming Care for Minors
Federal regulators have finally gotten off the bench and are putting the transgender medical industry under the microscope. The Federal Trade Commission (FTC) announced a sweeping investigation into whether hospitals, doctors, and pharmaceutical companies have been peddling risky and irreversible treatments to children—without being honest about the dangers or long-term consequences. At the heart of the probe: have families been sold a bill of goods in the name of “gender-affirming care,” or are critics overreacting to what activists call life-saving medicine?
The move comes just weeks after President Trump signed an executive order ending all federal support for gender-affirming care for minors, denouncing the procedures as “radical and false claims” that children’s sex can be changed with hormones and surgery. The order unleashed a wave of federal scrutiny, with the FTC, Department of Justice, and Centers for Medicare and Medicaid Services launching parallel investigations into whether providers have committed fraud, failed to obtain genuine informed consent, or misled families about the risks involved. The FTC’s July 9, 2025, workshop, “The Dangers of Gender-Affirming Care for Minors,” featured testimony from whistleblowers, detransitioners, parents, and ethicists, all raising the alarm about what they call a pattern of deception and ideological overreach.
Hospitals and Providers Shutter Services Amid Legal Threats
Medical institutions aren’t waiting around to see what happens next. Across the country, hospitals have begun shuttering or pausing their transgender clinics for minors—even in states where these procedures remain legal. The reason? Fear of losing federal funding, getting slapped with lawsuits, or being hauled into court for deceptive practices. This is a far cry from just a year ago, when these same providers were touting gender-affirming treatments as a moral imperative and “settled science.”
The chilling effect is real: families now find themselves caught in a regulatory crossfire, sometimes unable to access care at all. Some parents have reported total confusion as the rules shift beneath their feet, with clinics canceling appointments and scrambling to rewrite consent forms. Meanwhile, pharmaceutical companies that manufacture puberty blockers and cross-sex hormones are also under investigation for marketing these drugs off-label and failing to disclose the full extent of the risks.
Detransitioners and Whistleblowers: “We Were Lied To”
The most damning testimony at the FTC workshop came from detransitioners—young people who regret their medical transitions—and whistleblowers from inside the industry. They paint a picture of a system that, in their words, has prioritized ideology and profit over science and truth. Detransitioners like Prisha Mosley and Claire Abernathy described being rushed into irreversible treatments as teenagers, with little explanation of the risks or alternatives. Parents testified they were misled about success rates and the permanence of these interventions.
Advocacy groups such as Do No Harm argue that Section 5 of the FTC Act gives regulators all the authority they need to go after not just misleading advertisements, but the entire apparatus pushing “transgender ideology” on children. Dr. Miriam Grossman, a psychiatrist and leading critic, called the past decade of gender-affirming medicine “fraud and deceptive practice everywhere, going back decades.” FTC Chairman Andrew Ferguson, for his part, says there’s no need for lengthy new rulemaking: “If people are making material misstatements, sue them… We should prosecute deceptive health claims here like we do in every other sector.”
Federal Crackdown or Government Overreach?
Predictably, LGBTQ+ health advocacy groups have sounded the alarm about what they see as massive government overreach. They warn that the threat of federal enforcement is causing hospitals to abandon vulnerable youth and stifling medical innovation. Yet, the facts remain: the FTC has a long history of going after snake-oil salesmen, quack cures, and false health claims. Is it really so outlandish to apply those same standards to an industry that has exploded in size, profit, and controversy—especially when children are the target?
The stakes could not be higher. The FTC is gathering evidence, seeking public input, and preparing potential enforcement actions—including lawsuits, injunctions, and civil penalties. Other agencies, like the DOJ and CMS, are digging into informed consent violations and possible Medicaid fraud. The outcome could redefine not just transgender medicine, but the entire landscape of pediatric informed consent and medical ethics. For now, the only certainty is that the days of rubber-stamping radical medical interventions for kids, without serious scrutiny, are over.
Sources:
Axios, July 9, 2025: “Trump administration probes lead to trans care cutbacks”
Click this link for the original source of this article.
Author: Editor
This content is courtesy of, and owned and copyrighted by, https://www.rightwing.org and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
